Sutro Biopharma STRO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's retained earnings?
- Sutro Biopharma (STRO) reported retained earnings of -$1.02B in Q1 2026.
- How has Sutro Biopharma's retained earnings changed year-over-year?
- Sutro Biopharma's retained earnings decreased by 17.8% year-over-year, from -$862.84M to -$1.02B.
- What is the long-term trend for Sutro Biopharma's retained earnings?
- Over 5 years (2020 to 2025), Sutro Biopharma's retained earnings has grown at a 33.8% compound annual growth rate (CAGR), from -$227.87M to -$977.96M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.